Skip to content
Baltimore News Journal – Lifestyle
Author:
Nouscom Srl
Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers
June 1, 2026